Ovation Science Inc. (CSE:OVAT) and (OTC PINK:OVATF) ("Ovation" or the "Company") is pleased to announce it has received a further order for its DermSafe® hand sanitizer lotion from its distributor, Grupo Venta International, S.A. de C.V. ("Grupo Venta"), with corporate offices in Guadalajara, Mexico. They have been successfully selling DermSafe personal use sized bottles through-out Mexico and this new order represents a request for a new larger 944 ml. (32 oz.) DermSafe bottle for use by hospitals, large businesses and schools. As the recommended application is 1 ml per use, this larger size will have over 940 applications.

Grupo Venta provides Ovation with the ability to expand its sales of DermSafe hand sanitizer through their robust distribution network. Grupo Venta supplies surgical equipment, supplies, cosmetic and wellness products through-out Mexico. Their forty-six sales representatives target doctors across the country including over 3,000 dermatologists, 1,900 surgeons and other medical specialists and hospitals. Grupo Venta also utilizes a B2B and B2C strategy which focuses on bringing post-surgical and dermatology products to be sold in doctors' offices as well as retail and on their online portal called "Top Care Store". Additionally, Grupo Venta has a retail and online strategy for wellness products marketed by department stores, pharmacies and through various other online marketplaces in Mexico.

"We are very pleased with the success Grupo Venta has had selling DermSafe through their medical and consumer distribution channels," said Terry Howlett, President of Ovation. "Since DermSafe is made without alcohol and has the added benefit of our proprietary polymer delivery system Invisicare®, it really is a game changer in the industry. The increased hand-washing and use of alcohol has caused many issues for doctors and other medical professionals that constantly wash and reapply." He added, "Grupo Venta understands the need for a pharmaceutical-grade hand sanitizer like DermSafe and has the distribution network to make it available to the medical industry and consumers in Mexico."

DermSafe is a pharmaceutical-grade hand sanitizer lotion that uses chlorhexidine gluconate; an ingredient used worldwide in hospital soaps as it has a proven ability to kill gram negative and gram-positive bacteria as well as the envelope viruses. COVID-19 is an envelope virus. DermSafe has been developed with patented Invisicare® technology, which helps hands stay protected and as it contains no alcohol; it does not dry-out your hands. DermSafe is a recipient of the Canadian Dermatology Review Panel's "Seal of Approval".

According to www.statista.com, in Mexico, revenue in the Hand Sanitizer segment is projected to reach US$133.59m in 2021. The market is expected to grow annually by 10.0% (CAGR 2021-2025). There are over 1.5 million cases of COVID-19 in Mexico and currently five states are designated "red"; allowing only essential activities. Ovation is pleased that it can give people access to DermSafe to help keep them stay safe during these incredibly tough times.

For information about DermSafe and how to order visit https://dermsafe.com

For information about Ovation Science visit https://ovationscience.com.

Statements have not been evaluated by the Food and Drug Administration or Health Canada. These products are not intended to diagnose, treat, cure, or prevent any disease.

About Ovation Science Inc.
Ovation Science Inc. is a research and development company that develops topical and transdermal consumer products including DermSafe, all made with patented Invisicare® skin delivery technology. The technology enhances the delivery of ingredients to and through the skin and is protected by patents in eleven countries. With over twenty years of topical and transdermal drug delivery experience in the pharmaceutical market, Ovation's management and science team have created a unique pipeline of over twenty-five patent-protected medical / wellness topical and transdermal products along with a line of anti-aging / beauty formulas. Ovation earns revenues from licensing and development fees, royalties, the sale of Invisicare to its licensees and now revenue from its own product sales. Ovation has offices in Vancouver, BC Canada and Las Vegas, Nevada, USA. Ovation trades on the CSE under the symbol OVAT. Visit our website www.ovationscience.com.

Forward-Looking Statements
Information set forth in this news release contains forward-looking statements that are based on assumptions as of the date of this news release. These statements reflect management's current estimates, beliefs, intentions and expectations and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. In particular there is no assurance that the Company's DermSafe product will be licensed or approved for sale in Mexico, and that if approval is obtained that it will result in sales. Although DermSafe has been tested against other envelope viruses there is no assurance that it will kill or be as effective against COVID-19. In addition there is no assurance the Company's level of sales will continue or will not be negatively impacted by increased competition and recovery from the coronavirus pandemic. Other examples of the assumptions underlying the forward-looking statements contained herein include, but are not limited to those related to: strategies, potential sales, distribution and manufacturing of the Company's product as well as its effectiveness against COVID-19, the Company's ability to receive regulatory approval outside of Canada. There are no guarantees of future performance. Ovation Science Inc. cautions that all forward looking statements are inherently uncertain and that actual results may be affected by a number of material factors, many of which are beyond Ovation Science Inc.'s control. Accordingly, readers should not place undue reliance on the forward-looking information. Ovation disclaims any obligation to revise or update any such forward-looking information to reflect future results, events or circumstances, except as required by law.

Statements have not been evaluated by the Food and Drug Administration or Health Canada. These products are not intended to diagnose, treat, cure, or prevent any disease. Ovation does not sell or distribute any products that are in violation of the United States Controlled Substances Act (US.CSA).

Neither the Canadian Securities Exchange nor its Regulation Services Provider accepts responsibility for the adequacy or accuracy of this release.

CONTACT:
INVESTOR RELATIONS:
Sebastian Kunyz: This email address is being protected from spambots. You need JavaScript enabled to view it. Phone: 604-684-6730 or Toll Free at 866-684-6730

FOR BUSINESS DEVELOPMENT & CORPORATE INQUIRIES:
Doreen McMorran: This email address is being protected from spambots. You need JavaScript enabled to view it. Phone: 604-283-0903 ext. 4